Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9208976 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL9205224 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL9727986 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL336792 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL9200520 | 0.92 | ALDH1A1 (0.41) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL9202856 | 0.90 | ALDH1A1 (0.40) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL9728345 | 0.90 | ALDH1A1 (0.40) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL28694366 | 0.89 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL9687135 | 0.89 | POLB (0.45) | ALDH1A1MAPTHPGDTDP1ATM | |
| SCHEMBL28712277 | 0.89 | POLB (0.45) | ALDH1A1MAPTHPGDTDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-11981667-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| CN-114773248-B | Continuous production method and device for meropenem side chain | 湖北华洲药业有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-11465992-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2022-10-11 | — | — | US | disclosed |
| CN-114773248-A | Continuous production method and device for meropenem side chain | 湖北华洲药业有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3978489-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3661925-B1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2021-11-24 | — | — | EP | disclosed |
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | ORCHID PHARMA LTD. (IN) | 2021-11-23 | — | — | US | disclosed |
| US-20200291029-A1 | CARBAPENEM COMPOUNDS | MERCK SHARP & DOHME CORP. | 2020-09-17 | — | — | US | disclosed |
| US-20120065392-A1 | METHOD FOR PREPARING MEROPENEM USING ZINC POWDER | DAEWOONG BIO INC. (KR) | 2012-03-15 | — | — | US | disclosed |
| EP-2407468-A2 | IMPROVED METHOD FOR PREPARING MEROPENEM USING ZINC POWDER | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-01-18 | — | — | EP | disclosed |
| US-8097719-B2 | Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem | Genesen Labs (IN) | 2012-01-17 | — | — | US | disclosed |
| EP-2326648-A1 | PROCESS FOR THE PREPARATION OF CARBAPENEM COMPOUNDS | Ranbaxy Laboratories Limited (IN) | 2011-06-01 | — | — | EP | disclosed |
| US-20090299057-A1 | MEROPENEM INTERMEDIATE IN NOVEL CRYSTALLINE FORM AND A METHOD OF MANUFACTURE OF MEROPENEM | KHEMKA ASHWIN A | 2009-12-03 | — | — | US | disclosed |
| EP-1776365-A1 | MEROPENEM INTERMEDIATE IN CRYSTALLINE FORM | Sandoz AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20070037971-A1 | PROCESS FOR DESILYLATION OF CARBAPENEM INTERMEDIATES | RANBAXY LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | US | disclosed |
| WO-2005118586-A1 | MEROPENEM INTERMEDIATE IN CRYSTALLINE FORM | SANDOZ AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| EP-0126587-B1 | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof | SUMITOMO PHARMA (JP) | 1995-04-19 | — | — | EP | disclosed |
| EP-0126587-A1 | Carboxylic thio-pyrrolidinyl beta-lactam compounds and production thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299057-A1 | MEROPENEM INTERMEDIATE IN NOVEL CRYSTALLINE FORM AND A METHOD OF MANUFACTURE OF MEROPENEM | NT5C3B, CYP4B1, GNE | ALDH1A1 4012/4885MAPT 1931/4885HPGD 209/4885 |
| US-11180504-B2 | Substituted carbapenems for the treatment of bacterial infections | SLC11A2, GSK3B, GSK3A | ALDH1A1 3598/4885MAPT 4569/4885HPGD 813/4885 |
| US-20120065392-A1 | METHOD FOR PREPARING MEROPENEM USING ZINC POWDER | SLC39A3, SLC30A6, SLC30A5 | ALDH1A1 3866/4885MAPT 1535/4885HPGD 2187/4885 |
| US-20070037971-A1 | PROCESS FOR DESILYLATION OF CARBAPENEM INTERMEDIATES | ADSL, ACSL3, AGL | ALDH1A1 4044/4885MAPT 2697/4885HPGD 1902/4885 |
| US-20200291029-A1 | CARBAPENEM COMPOUNDS | GSK3B, GSK3A, GNE | ALDH1A1 3320/4885MAPT 3938/4885HPGD 211/4885 |
| US-11981667-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | ALDH1A1 640/4885MAPT 3045/4885HPGD 2410/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | ALDH1A1 754/4885MAPT 3006/4885HPGD 2900/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | ALDH1A1 671/4885MAPT 3091/4885HPGD 2568/4885 |
| US-11465992-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | ALDH1A1 660/4885MAPT 3217/4885HPGD 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.